Biomedica

PulseCath

PulseCath® is the developer of ground-breaking technologies to assist the life sustaining pumping functions of the failing heart.The Company holds rights to the invention of the iVAC system, a broad base proprietary technology to fill the void in cardiac assist, between the low end intra-aortic balloon pump (IABP) and the complex, expensive implantable, or external ventricular assist devices (VAD).The iVAC product collection offer the advantage of greater cardiac output than IABP, with increased end-organ perfusion, mechanical unloading of the heart and optimization of conditions for myocardial recovery.

iVac 2L™ Femoral
The iVAC 2L is a short term minimally invasive trans femoral fully percutaneous catheter based cardiac assist, with a patented two-way valve that aspirates blood from the left ventricle and displaces it into the ascending aorta. It rapidly unloads the left ventricle and consequently increases effective forward flow of blood without causing any significant hemolysis.

Link to Pulsecath

Back to list